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Abstract 
Background: Cancer and coagulation activation are tightly related. The extent to which factors related to both these 
pathologic conditions concur to patient prognosis intensely animates the inherent research areas. The study herein 
presented aimed to the development of a tool for the assessment and stratification of risk of death and disease recur‑
rence in early breast cancer.
Methods: Between 2008 and 2010, two hundreds thirty‑five (N: 235) patients diagnosed with stage I–IIA breast can‑
cer were included. Data on patient demographics and clinic‑pathologic features were collected in course of face‑to‑
face interviews or actively retrieved from clinical charts. Plasma levels of plasminogen activator inhibitor type 1 (PAI‑1), 
fragment 1 + 2 (F1 + 2), thrombin antithrombin complex (TAT), factor VIII (FVIII), and D‑dimer (DD) were measured at 
breast cancer diagnosis and prior to any therapeutic procedure, including breast surgery. The risk of death was com‑
puted in terms of overall survival (OS), which was the primary outcome. For a subset of patients (N = 62), disease free 
survival (DFS) was also assessed as a measure of risk of disease recurrence.
Results: Median follow up was 95 months (range 6–112 months). Mean age at diagnosis was 60.3 ± 13.4 years. 
Cancer cases were more commonly intraductal carcinomas (N: 204; 86.8%), pT1 (131; 55.7%), pN0 (141; 60%) and G2 
(126; 53.6%). Elevated levels of PAI‑1 (113; 48.1%) represented the most frequent coagulation abnormality, followed 
by higher levels of F1 + 2 (97; 41.3%), DD (63; 27.0%), TAT (34; 40%), and FVIII (29; 12.3%). In univariate models of OS, 
age, pT, DD, FVIII were prognostically relevant. In multivariate models of OS, age (p = 0.043), pT (p = 0.001), levels of 
DD (p = 0.029) and FVIII (p = 0.087) were confirmed. In the smaller subgroup of 62 patients, lymph node involvement, 
percent expression of estrogen receptors and levels of FVIII impacted DFS significantly.
Conclusions: We developed a risk assessment tool for OS including patient‑ and cancer‑related features along with 
biomarkers of coagulation activation in a cohort of early BC patients. Further studies are warranted to validate our 
prognostic model in the early setting and eventually extend its application to risk evaluation in the advanced setting 
for breast and other cancers.
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Background
In recent years, the body of knowledge supporting 
the mutual association between coagulation disorders 
and cancer has notably grown [1, 2]. Cancer is a widely 
accepted predisposing factor for thromboembolic events. 
At the general population level, these events show an 
incidence rate of one to two per 1000 people/year, while 
patients with malignancies generally exhibit a 4–10 times 
greater risk, which may further increase particularly in 
pancreatic and brain cancer patients [3–5]. Beyond the 
primitive cancer site, several clinicopathologic features 
and administered treatments have been consistently 
described as specific determinants of venous thrombo-
embolism (VTE) in patients with cancers [6, 7].
On the other side of the medal, biomarkers related to 
coagulation disorders have shown prognostic relevance 
in lung, colorectal, ovarian cancer and glioblastoma, 
independently on the occurrence of VTE [8–11]. When 
focusing on breast malignancies, rapidly growing evi-
dence comes from both the advanced and early setting. 
In 84 patients with metastatic disease, pre-treatment 
plasma levels of D Dimer (DD) were positively associated 
with prognostically relevant clinicopathologic features 
and circulating levels of cytokines related to angiogenesis 
[12]. More recently, circulating tumour cells (CTC) have 
been linked to plasma DD levels in patients with meta-
static breast cancer. This latter study also confirmed the 
previously described association between CTC and VTE 
[12, 13]. Evidence from the early setting is also intriguing. 
In a case–control study of genotypic and phenotypic var-
iables related to the tissue factor (TF) pathway, DD levels 
beyond the 90th percentile were associated with cancer 
status, with results being not specific to the different sub-
sets of patients as defined by hormone receptor (HR) and 
HER2 status [14]. In 360 HR negative early breast cancer 
patients, positive staining at the immunohistochemical 
assessment of D2-40 and factor VIII (FVIII) was associ-
ated with less favorable survival outcomes both in the 
overall cohort and in patient subgroups [15]. In addition, 
in a case series including 100 women having undergone 
breast surgery due to newly diagnosed invasive breast 
cancer, circulating levels of FVIII were significantly asso-
ciated with axillary lymph node involvement, number of 
metastatic nodes, and HER2 status [16].
Based on the previously cited work and institutional expe-
rience of dedicated scientists operating in the management 
of thrombosis in cancer, we have gained increasing aware-
ness of the need of considering biomarkers related to coagu-
lation disorders in the evaluation of treatment outcomes in 
breast cancer. We have thus focused on the development of 
an operating tool for risk assessment based on the combined 
evaluation of patient- and cancer-related features along with 
biomarkers of coagulation disorders. Among these latter 
biomarkers, we have specifically focused on plasmatic fac-
tors which play a relevant role in terms of activators of blood 
coagulation. To this aim, we have conceived and conducted 
a monocentric observational study in a cohort of early 
breast cancer patients diagnosed and treated at our institu-
tion between 2008 and 2010.
Methods
Patients and setting
We analyzed records related to two hundreds thirty-
five (N: 235) patients diagnosed with stage I–IIA breast 
cancer and treated at the IRCCS Regina Elena National 
Cancer Institute of Rome (IRE) between 2008 and 2010. 
For all of them, data on demographics and key clinico-
pathologic features were actively retrieved by ad hoc 
trained personnel. In addition, plasma levels of plasmino-
gen activator inhibitor type 1 (PAI-1), prothrombin frag-
ments 1 + 2 (F1 + 2), thrombin antithrombin complex 
(TAT), FVIII, and DD were measured at baseline prior to 
any therapeutic procedure, including surgery. For a sub-
set of these patients (N: 62), data on anticancer systemic 
treatment were made available and analyzed in reference 
to the outcomes of interest. Disease free survival (DFS) 
and overall survival (OS) were computed as the time 
elapsed between the histologically codified diagnosis 
performed in surgical specimen and disease progression 
or death from any cause, and the time from diagnosis to 
death due to any cause, respectively. The study was con-
ducted in accordance with the Declaration of Helsinki 
and approved by the IRE Institutional Review Board 
(IRB). For each participating woman, a written informed 
consent was secured in case of patient acceptance fol-
lowing invitation to adhere. This study is compliant with 
the REMARK guidelines, in that it provides relevant 
information concerning its design, underlying hypoth-
esis, characteristics of the included patients and collected 
specimen, assay methods, and statistical analysis [17].
Blood sampling and biomarker assessment
Blood samples were drawn from the antecubital veins 
and collected in 3.2% sodium citrate  vacutainer® vacuum 
tubes (Vacutainer, Becton–Dickinson, Franklin Lakes, NJ 
USA). Identical blood collecting procedures were applied 
to the samples from a control group including 150 cancer-
free women seeking blood screening tests at the IRE. The 
two groups were comparable by age and date at assess-
ment (data available upon request). Blood samples were 
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centrifuged at 2500g for 20  min to obtain platelet-poor 
plasma. Plasma levels of DD and FVIII were immedi-
ately assayed by clotting, chromogenic and immunologi-
cal methods on fully-automated ACLTOP analyzer using 
 HemosIL® commercial kits (Instrumentation Laboratory 
Company, Bedford, MA USA). Plasma samples were then 
separated and stored into multiple aliquots at − 80  °C 
for subsequent testing. Plasma levels of TAT and F1 + 2) 
were measured by enzyme-linked immunosorbent assay 
 Enzygnost® TAT micro and  Enzygnost® F1 + 2 mono kits, 
respectively (Siemens Healthcare Diagnostics Inc, NY 
USA), according to the manufacturer instructions. Both 
assays employ the quantitative sandwich enzyme immu-
noassay technique. All samples showing values above the 
standard curve were re-tested with appropriate dilutions. 
Plasma levels ofPAI-1 were determined by  Asserachrom® 
kit (DiagnosticaStago, Asnieres, France), according to the 
manufacturer instructions, employing the quantitative 
sandwich enzyme immunoassay technique.
Statistical analysis
Descriptive statistics were computed for all the variables 
of interest. Means and standard deviations (SD) were 
used to describe age in years, circulating levels of coagu-
lation activators and define cut off points discriminating 
between case and control patients. Categorical variables 
were addressed by χ2 test or Fisher’s exact test, according 
to the size and number of groups compared, i.e., two or 
more than two, respectively. Disease-free Survival (DFS) 
and OS were calculated by the Kaplan–Meier product 
limit method. The log-rank test was used to assess dif-
ferences between subgroups. Significance was set at a p 
value less than 0.05. The hazard ratio (HR) and the 95% 
confidence intervals (95% CI) were estimated for each 
variable using the Cox univariate model. The following 
variables were tested in univariate analyses: age, tumor 
size at the post surgical assessment (pT), pathologic loco-
regional nodal involvement (pL), grading (G), estrogen/
progestin receptor (ER/PgR) expression, HER2 status, 
molecular subtype (triple negative, luminal A, luminal B, 
HER2 enriched breast cancer subgroups), percentage of 
ki-67 expression (ki-67%). The coagulation biomarkers 
tested were as it follows: PAI-1, f 1 + 2, TAT, FVIII and 
DD. Variables testing significant in univariate analysis 
were included in multivariate models using the stepwise 
regression (forward selection, enter limit and remove 
limit, p = 0.10 and p = 0.15, respectively). The outcome 
predictors identified on the basis of the multivariate 
analysis were then used for prognostic score assessment. 
The log-HR obtained from the Cox model was used 
to derive weighting factors of a continuous prognostic 
index, aimed to identify differential risks for the out-
come of interest [18]. Risk classes were derived using the 
maximally selected log-rank statistics analysis for the 
best ‘splitter’ cut-off definition [19]. The SPSS (version 
21.0; SPSS, Inc., Chicago, IL) and R-Software (version 
3.4.2) were used for statistical analyses.
Results
The median follow up for the overall cohort was 
95  months (6–112). The descriptive characteristics of 
our study participants are displayed in Table  1. Mean 
Table 1 Clinical-pathological characteristics of  the  study 
participants (N: 235)
Characteristics Number (N) 
and percentage 
(%)
Age (years) N (%)
Mean (SD) 60.3 (13.4)
Histology
 Intraductal carcinoma 204 (86.8)
 Lobular carcinoma 14 (6.0)
 Other 9 (3.8)
 Unknown 8 (3.4)
pT stage
 pT1 131 (55.7)
 pT2 104 (44.3)
pN stage
 pN0 141 (60.0)
 pN1 83 (35.3)
 Unknown 11 (4.7)
Grading
 1 16 (6.8)
 2 126 (53.6)
 3 64 (27.2)
 Unknown 29 (12.3)
Estrogen receptor status
 Positive 186 (79.1)
 Negative 49 (20.9)
Progesterone receptor status
 Negative 71 (30.2)
 Positive 164 (69.8)
HER2 status
 Positive 39 (16.6)
 Negative 196 (83.4)
% Ki‑67
 ≤ 15 142 (60.4)
 > 15 89 (37.9)
 Unknown 4 (1.7)
Molecular subtype
 Triple‑negative 30 (12.8)
 Luminal A 118 (50.2)
 Luminal B 69 (29.3)
 HER2‑enriched 18 (7.7)
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age at diagnosis and related SD were 60.3 ± 13.4. As 
expected, the most commonly represented histology 
was intraductal carcinoma (204; 86.8%). Cancer cases 
were most commonly pT1 (131; 55.7%), pN0 (141; 60%) 
and G2 (126; 53.6%). Overall, based on ER/PgR expres-
sion, HER2 status, and ki-67%, the number and percent-
ages of luminal breast cancers, triple negative (TN) and 
HER2 enriched cases were 187 (79.5%), 30 (12.8%) and 18 
(7.7%), respectively.
The number and percentage of early breast cancer 
patients with abnormal levels of biomarkers related to 
coagulation activation are reported in Table  2. Among 
our early breast cancer patients, elevated levels of PAI-1 
(113; 48.1%) were those most commonly observed, 
followed by higher levels of F1 + 2 (97;41.3%), DD 
(63;27.0%), TAT (34;40%), and FVIII (29;12.3%).
Among the factors included in univariate models of 
OS, those testing significant were age, pT, DD, and FVIII. 
In brief, breast cancer patients had the highest chances of 
longer survival if aged 60 years or less (p = 0.0002), show-
ing a pT1 (p = 0.0007), normal levels of FVIII (p = 0.003), 
and lower levels of DD (p = 0.001) (Fig.  1a–d). In addi-
tion, patients with no lymph-node involvement and lower 
levels of PAI-1 showed longer survival, although not to 
an extent that was statistically significant (p = 0.05 and 
p = 0.08, respectively) (data available upon request). In 
multivariate models, age (p = 0.043), pT (p = 0.001), levels 
of DD (p = 0.029) and FVIII (p = 0.087) were confirmed 
as factors of relevant impact on OS. The related HR, 95% 
CI and p are shown in Table 3.
As mentioned in the “Methods” section, variables 
testing significant in multivariate analysis were used for 
prognostic score assessment. Determinants of OS con-
tributed to risk definition and assignment to risk cat-
egories according to the best ‘splitter’ cut-off definition 
as applied to this specific cohort (Table  4). The inher-
ent results are graphically displayed in Fig.  2. In brief, 
breast cancer patients within the lowest risk category, 
i.e., with age younger than 70, pT1, circulating levels of 
FVIII within the normal range, and low levels of DD, 
showed significantly longer OS compared to the groups 
of patients at intermediate and high risk, with the related 
HRs being 95.6, 77.2, and 55.0, respectively (p < 0.0001).
In a subset of patients (N: 62) for whom data related 
to administered treatments and related outcomes were 
available, we estimated DFS and OS. Prior to perform-
ing such analyses and in order to minimize the chances of 
selection bias, we compared the sub-cohort of interest (N: 
62) and its complement to the overall cohort (N: 173) by 
relevant characteristics. Results showed statistically sig-
nificant differences in terms of age when using the cut off 
value of 70 (p = 0.04), which had been previously defined 
as the most efficient splitter for the overall cohort. How-
ever, when comparing the two subgroups by median age, 
this difference was no longer observed (55 years within a 
35–87 range and 60 within a 29–89 range for the smaller 
and larger subset, respectively). In the smaller subgroup, 
we tested the variables included in the scoring tool in 
multivariate Cox models of DFS, which revealed signifi-
cant prognostic relevance for lymph node involvement, 
percent expression of ER and levels of FVIII (Additional 
file  1: Table  S1). However, the low number of recur-
rences, i.e., 12, prevented us from applying the scoring 
tool for risk stratification in this subset. Similarly, when 
considering OS, the number of events was extremely low, 
i.e., 8 (median OS not reached). This prevented us from 
performing additional analyses.
Discussion
We conducted an observational study of 235 early breast 
cancer patients who were diagnosed and treated at the 
IRCCS Regina Elena Cancer Institute in the time frame 
between July 2008 and September 2010. For all of them, 
blood samples were collected prior to any therapeutic 
procedures and assessed for circulating levels of bio-
markers related to coagulation activation. One hundred 
fifty cancer free women comparable by age and recruit-
ment period served as control group. Data analysis were 
planned and performed to allow the development of a 
tool instrumental to the assessment of risk categories 
based on features related to relevant clinicopathologic 
characteristics and coagulation profiling for the biomark-
ers of interest. Within our study population, results from 
multivariate analysis revealed a prognostic role for age, 
pT, circulating levels of FVIII and DD. These variables 
were then used to define risk categories, with cut off 
points obtained by applying the best “splitter” cut-off def-
inition to our case-series. The so developed tool proved 
efficacy in distinguishing categories characterized by 
significantly different survival estimates. In more detail, 
Table 2 Abnormal levels of  biomarkers related 
to coagulation disorders in our study cohort (N: 235)
PAI-1 plasminogen activator inhibitor type 1, F1 + 2 fragment 1 + 2, TAT thrombin 
antithrombin complex, FVIII factor VIII, DD d-dimer
a Cut-off values for case discrimination were defined upon the mean + 2SD of 
each biomarker as assessed in the control group (N: 150)
Variable N Mean (SD) Patients with abnormal 
levels of biomarkers N 
(%)a
DD 232 215.13 (174.47) 63 (27.0)
TAT 235 4.94 (3.23) 34 (40.0)
F 1 + 2 235 207.76 (81.18) 97 (41.3)
PAI‑1 235 32.46 (23.61) 113 (48.1)
FVIII 235 131.28 (33.65) 29 (12.3)
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the lowest risk of death from any cause was ascribed 
to patients aged 70  years or less, with a pT1 disease at 
diagnosis, circulating levels of FVIII within the normal 
range and low levels of DD. Age older than 70 years and 
FVIII levels greater than the pre-established cut off val-
ues where instead associated with an intermediate risk of 
death, while the highest risk of death was associated with 
a pT2 and DD levels beyond the threshold defined for our 
study population.
Among the clinically relevant patient- and disease-
related determinants of interest, age and tumour size 
(pT) showed prognostic relevance in uni- and multi-
variate analysis and were thus included in the model for 
risk stratification. This evidence is consistent with pre-
vious literature from the early setting [20, 21]. In strict 
regard to the patient age, our results provide several hints 
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Fig. 1 Overall survival by relevant clinical pathologic features and biomarkers of coagulation activation. a Overall survival (OS) by age at breast 
cancer diagnosis. The cut off was defined upon the median age at the study population level; b overall survival (OS) by T size as assessed by the 
pathologist on surgical specimen (pT); c overall survival by plasmatic levels of Factor VIII (FVIII). d Overall survival (OS) by plasmatic levels of D‑Dimer 
(DD)
Table 3 Multivariate analysis of  factors impacting overall 
survival (N: 235)
FVIII factor VIII, DD d-dimer
Variable HR (CI 95%) p
Age year (> 70 vs ≤ 70) 2.35 (1.026–5.396) 0.043
pT stage (pT2 vs pT1) 4.96 (1.99–12.38) 0.001
DD (high vs low) 3.17 (1.13–8.94) 0.029
FVIII (abnormal vs normal) 2.15 (0.90–5.15) 0.087
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for discussion. In our case series, values of median age 
and best “splitter” cut-off for age were 60 and 70  years, 
respectively. In addition, the outcome considered for the 
overall case series was death from any cause as we lacked 
data on breast cancer specific mortality for the totality of 
our patients, as specifically pointed out in the paragraph 
concerning this study limitations. Thus, we addressed 
an outcome, i.e., death from any cause, which is defi-
nitely affected by aging. Indeed, the lack of specific data 
concerning the extent to which age, co-morbidities, and 
breast cancer have concurred to determine our patients’ 
death may be more appropriately exemplified by the use 
of a terminology distinguishing between “likely cause of 
death” vs “other causes of death”, particularly in light of 
the broad age range which characterizes our case-series, 
i.e., 29–39 years. The relation between aging and breast 
cancer is complex and the investigation of the underly-
ing mechanisms animates intensely the inherent research 
area [22]. In reference to recently published and clinically 
focused evidence, Lodi et al. have evaluated relevant clin-
icopathologic features and breast cancer specific survival 
outcomes in a systematic review of women over 70 years 
with breast cancer. Sixty-three original studies published 
between 2006 and 2016 were considered. Consistently 
with our findings, the authors reported on the associa-
tion between older age and significantly higher 5- and 
10-year mortality [23]. Older age at breast cancer diagno-
sis should be considered not only in light of its prognostic 
role for the disease of interest, but also in reference to the 
role of DD and FVIII as biomarkers of aging, widely and 
consistently supported by the inherent literature in both 
non-cancer and cancer patients [24–28]. On this basis 
and in strict regard to our study population, we assessed 
the interaction between age and circulating levels of DD 
and FVIII in Cox models including an interaction term. 
In this specific cohort, we could not observed significant 
interaction between the variables tested (p = 0.20 and 
p = 0.94, for the interaction between age and DD and 
FVIII, respectively).
In this study population, we found no evidence sup-
porting the prognostic relevance of the specific molecu-
lar subtype, i.e., luminal A, luminal B, HER2 enriched 
and triple negative breast cancer, on patient survival. 
Indeed, in multivariate analysis of OS, the related vari-
ables tested not significant (p: 0.74). This finding, i.e., lack 
of the impact of molecular subtype on the outcomes of 
interest in a breast cancer patient population from the 
early setting, is consistent with previous studies [14, 16] 
and in need of further assessment for clarification pur-
poses. Indeed, in our case series, we exclusively observed 
some evidence of the prognostic relevance of ER expres-
sion, one of the main determinants of the specific molec-
ular subgroups, in the subset of patients for whom DFS 
data were available (N: 62), with our results supporting 
a protective role of ER expression (p: 0.003). This same 
patient subgroup also offered the chance for evaluating 
our scoring tool in reference to DFS. Although somewhat 
limited by the restricted sample size, results from the 
analysis performed within this subset confirm the prog-
nostic relevance of biomarkers related to coagulation dis-
orders, and the need for including such evidence in risk 
assessment for early breast cancer patients.
An appropriate discussion of our results cannot 
exclude a referral to the existing evidence concerning 
the use of anticoagulants in cancer patients, which has 
been recently summarized in a Cochrane systematic 
review carried out by Kahale et  al. In brief, the authors 
conducted a comprehensive literature search updated to 
December 2017. Of the identified 7668 unique citations, 
16 manuscripts reporting on 7 randomized clinical tri-
als (RCTs) fulfilled the inclusion criteria and were thus 
Table 4 Prognostic score assessment according 
to determinants of overall survival in our study cohort (N: 
235)
FVIII factor VIII, DD d-dimer
Overall survival Score points
0 1 2
pT T1 – T2
FVIII Normal Abnormal –
Age ≤ 70 > 70 –
DD Low – High
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Fig. 2 Overall survival (OS) according to risk categories as identified 
by the nomogram developed based on data from this historic cohort
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included. Overall, these trials enrolled 1486 participants. 
Results from the meta-analyses of the RCTs included do 
not rule out a mortality benefit from oral anticoagulation 
in people with cancer but suggest an increased risk for 
bleeding. In the attempt to interpret these findings cor-
rectly, the lack of data specifically referred to the site of 
cancer origin should be considered. Indeed, the need of 
further evidence specifically related to the cancer type 
and stage is acknowledged by the authors themselves 
when discussing their research implications [29].
The pathogenetic layout of the association between 
the activation of coagulation and cancer is multifacto-
rial in nature. In addition, most of the actors involved 
play a pivotal role in several mechanistic pathways that 
sustain cancer-related biological processes with a nota-
ble degree of overlap. The previously mentioned role of 
FVIII and DD as factors involved both in cancer, throm-
bogenesis and aging may appropriately exemplify this 
latter assertion [24–28]. Cancer may provide an unusual 
and polyvalent frame within which patient- and disease-
related features concur to outcome determinism, both for 
thromboembolic and cancer related events. The relation-
ship between thrombosis and cancer is founded on the 
evidence that cancer promotes a prothrombotic switch 
of the host hemostatic system, and in turn, blood clot-
ting activation is intimately tight to tumor growth and 
dissemination. The main mechanisms of cancer-related 
thrombosis encompass the expression of procoagulant 
factors at the tumour cell level, the release of micro-
particles, inflammatory cytokines e.g., tumor necrosis 
factor-alpha, interleukin-6, and proangiogenic factors, 
e.g., vascular endothelial growth factor, basic fibroblast 
growth factor by tumor and/or host cells, and the expres-
sion of adhesion molecules to bind platelets, endothe-
lial cells, and leucocytes. These same properties are also 
involved in cancer progression [30, 31].
Our study has some limitations, which are mainly rep-
resented by the lack of data concerning cancer-specific 
survival for the overall case series. This is unfortunately 
common when working in the real word setting. Indeed, 
data collection and entering into dedicated databases 
has not stably entered the clinical practice. To mitigate 
such limitation, we have attempted to perform subgroup 
analysis in a subset of patients for whom cancer-specific 
survival data were available. Unfortunately, this sub-
set was extremely limited in size (N: 62). This refrained 
us from conducting analysis beyond the multivariate 
models. However, also in this smaller subset, we could 
observe evidence supporting the prognostic relevance 
of both patient- and cancer-specific feature along with 
circulating levels of coagulation biomarkers. The lack of 
data on menopausal status should also be acknowledged, 
given the relevant differences in terms of risk factors, 
presentation at diagnosis, characteristics and manage-
ment between pre- and post-menopausal breast cancer 
patients [32–34]. In the attempt to minimize such limi-
tation, we codified a categorical variable with a 50-year 
cut off value and assumed that women aged less than 
50 years (N: 70; 25.5%) were most likely premenopausal. 
However, in univariate models of OS and DFS, our surro-
gate variable of menopausal status did not test significant 
(p: 0.32 and p: 0.81, respectively).
Our study also has strengths of relevance. Among 
them, central management of biomarkers of coagulation 
activation is noteworthy. Plasma samples were collected 
and handled according to pre-specified and highly stand-
ardized operative procedures. Sample assessment was 
performed at the institutional laboratories, which are 
ISO-certified (ISO 9001 certification). This increases our 
confidence in the quality of the evidence stemming from 
our study. As cited in the “Results” section, the median 
follow up for the cohort of interest was 95  months, 
which is fairly acceptable in terms of length when assess-
ing outcomes in a cohort of early breast cancer patients. 
However, this 10-year follow up window imposes con-
siderations related to the remarkable advances achieved 
both in the loco-regional and systemic treatment [35–40] 
and invites caution in the generalization of our results to 
early breast cancer patients in current treatment. At the 
same time, this latter matter, along with the results from 
the work herein presented, encourages future investiga-
tion within this same research pipeline.
Conclusions
We provide evidence in support of the prognostic rel-
evance of age at cancer diagnosis, pT, levels and FVIII 
and DD in a case-series including 235 stage I-IIA breast 
cancer patients. The score including these factors proved 
efficacy in distinguishing risk categories in reference to 
survival outcomes. Risk assessment and stratification 
for cancer related outcome deserves active investiga-
tion. To this purpose, the subsequent steps to be taken 
possibly include the validation of our model in independ-
ent cohorts of early breast cancer patients participating 
in adequately sized, ad-hoc, prospective studies. These 
latter studies should ideally allow the serial assessment 
of biomarkers of coagulation activation at pre-specified 
time points. This would allow to monitor these bio-
markers in parallel with the disease course and integrate 
the inherent data with those pertinent to breast can-
cer treatment and related outcomes. In addition, future 
studies should also include VTE-related outcomes, e.g., 
deep vein thrombosis, pulmonary embolism. These 
strategies may help compute multiple risk estimates 
for time dependent outcomes, e.g. DFS and OS, and, at 
the same time, help define more accurately the cause of 
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death. We would also acknowledge the potential use of 
data concerning the activation of coagulation as meas-
ured throughout the levels of circulating biomarkers in 
informing therapeutic decisions concerning the specific 
therapy to be administered in the adjuvant setting in 
light of the increased risk of VTE particularly, though 
not exclusively, associated with hormonal therapy [41]. 
The identification of the high-risk subgroups for both 
cancer- and coagulation-related death and establishment 
of the most appropriate therapeutic strategies possibly 
including antithrombotic agents is undeniably tighten 
to multidisciplinary efforts of medical oncologists and 
clinical pathologists with a solid background in the pre-
vention, diagnosis and management of cancer patients 
with prothrombotic alterations. A deeper and, as previ-
ously stated, multidisciplinary characterization of cancer 
patients represents the best prelude to outcome ame-
lioration and correct interpretation. If considering that 
about half of all cancer patients, and as many as 90% of 
those from the metastatic setting show abnormalities in 
one or more coagulation-related parameters [42], a still 
relevant number of queries concerning the management 
of these patients remain unsatisfactorily addressed and 
will hopefully fuel cancer research in the upcoming years.
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